JPMorgan Increases Price Target for Xenon Pharmaceuticals
On May 12, JPMorgan analyst Tessa Romero raised the price target on Xenon Pharmaceuticals (NASDAQ:XENE) to $80 from $77 while maintaining an Overweight rating. Wells Fargo also increased its price target slightly to $69 from $68 with a similar Overweight stance.
Topics: Biopharmaceuticals FDA Approval Outlook Neuroscience